[ad_1]
A two-week course of antiviral therapy combining the power of three drugs has shown promise in treating hospitalized patients with mild to moderate COVID-19 in a carefully conducted Phase 2 clinical trial.
The results of the trial, published in The Lancet, involved 127 adults from six public hospitals in Hong Kong.
The combination of drugs tested in the trial included interferon beta-1b, which was developed to treat multiple sclerosis (MS) and lopinavir-ritonavir, which is normally used to treat HIV and ribavirin, an oral drug for the HIV virus. hepatitis C.
Findings from the phase two trial provided evidence that early treatment with triple antiviral therapy in conjunction with standard care is safe and shortens the duration of virus clearance (when the virus is detectable and potentially transmissible) compared to lopinavir-ritonavir alone: average of seven days versus 12 days —In patients with mild to moderate COVID-19.
“Our trial demonstrates that early treatment of mild to moderate COVID-19 with a triple combination of antiviral drugs can rapidly suppress the amount of virus in a patient’s body, alleviate symptoms and reduce the risk to healthcare workers by reduce the duration and amount of viral excretion, “said Professor Kwok-Yung Yuen of the University of Hong Kong who led the research.
No new cases in Hong Kong as restrictions are eased
Hong Kong did not record any new cases of COVID-19 on Saturday, a day after the city eased the restrictions. Saturday was also the 20th consecutive day without local infections. Health experts previously suggested that Hong Kong could be considered free of local transmission if there were no such cases after 28 days.
Catch up on the latest News on crime, national, international and Hatke here. Also download the new noon Android and iOS applications to get the latest updates.
Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news
This story has been obtained from a syndicated feed from third parties, agencies. Mid-day does not accept any responsibility or liability for its reliability, reliability, reliability and data of the text. Mid-day management / mid-day.com reserves the exclusive right to alter, remove or remove (without notice) the content in its sole discretion for any reason.
